Enhancing innate anti-tumour immunity : lessons from virotherapy and STING agonism 1 / Kevin J. Harrington.

Format:

Video

Author/Creator:

Harrington, Kevin J., author.

Language:

English

Subjects (All):

Natural immunity.

Monoclonal antibodies.

Physical Description:

1 streaming video file (37 min., 48 sec.) : color, sound

Other Title:

Enhancing innate anti-tumour immunity

Place of Publication:

London : Henry Stewart Talks Ltd, 2024.

System Details:

video file

Contents:

Introduction

Declaration of interests

Systemic versus local delivery

Example of intratumoural injections

Intratumoural injections in head and neck cancer

Pattern recognition receptors activate innate immunity

Activation of pattern recognition receptors

Viruses as pathogens

Oncolytic viruses

Viruses in oncolytic therapy

T-VEC

Deletion of ICP34.5 attenuates replication

ICP34.5 deletion results in tumour-selective replication

T-VEC - local and systemic effects

A Phase I study of OncoVEXGM-CSF

Phase II clinical trial

Phase II clinical trial: lesions & survival

OPTiM Phase III trial (005/05)

OPTiM endpoints

64% of injected lesions responded to T-VEC

34% of non-injected non-visceral lesions responded to T-VEC

15% of visceral lesions responded to T-VEC

I.T. oncolytic viruses as immunomodulators

MASTERKEY-265 study

MASTERKEY-265 study: survival

MASTERKEY-265 study: response level

GALV - fusogenic membrane glycoprotein

GALV increases cytotoxicity and gene expression

GALV-expressing virus is more active in vivo

GALV-expressing virus increases immune infiltrates

GALV-expressing virus is active with anti-PD1 MAB

RP1 as a platform for next-generation viral immunotherapies

Thank you for listening.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved August 28, 2025, from https://doi.org/10.69645/FGVW6016.